Published in Cancer Weekly, November 2nd, 1998
The approach targets cancer-causing receptor molecules found on the surface of tumor cells with two different antibodies that bind to the molecules, fatally disabling the receptor's activity and leading to the cancer cell's death.
The specific application of the concept detailed in the patent employs a pair of antibodies against a receptor protein called p185. The p185 protein assembles into a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.